Home/Pipeline/SEL24 (MEN1703)

SEL24 (MEN1703)

Acute Myeloid Leukemia (AML)

Phase 1/2ActiveNCT03008187

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Phase 1/2

Status

Active

Company

Selvita

About Selvita

Selvita is a key player in the Central and Eastern European life sciences sector, combining a service-based contract research organization (CRO) business with proprietary drug development. The company's core expertise lies in integrated drug discovery, medicinal chemistry, and biology, which it applies to internal oncology programs and external partnerships. Its strategic direction involves advancing its pipeline of small molecule inhibitors while expanding its global CRO footprint. Key achievements include establishing long-term collaborations with major pharmaceutical companies and progressing several proprietary assets into clinical and pre-clinical stages.

View full company profile

Therapeutic Areas

Oncology

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
NTLA-5001	Intellia Therapeutics	Phase 1/2	Active
Galinpepimut-S (GPS)	SELLAS Life Sciences	Phase 2/3	Active
SLS009 (GFH009)	SELLAS Life Sciences	Phase 1/2	Active
UCART123	Cellectis	Phase 1	Active
Iadademstat (ORY-1001)	Oryzon Genomics	Phase 2	Active - Combination with azacitidine
MP0533	Molecular Partners	Phase 1/2	Active
Selinexor	Karyopharm Therapeutics	Clinical Trials	Investigational
NEX-20 (azacitidine)	Nanexa AB	Phase 1	Active
SENTI-202	Senti Biosciences	Phase 1	Active - Global clinical trial ongoing
motixafortide (BL-8040)	BioLineRx	Phase 2a	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)